Logo

Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany

Share this

Alnylam Launches Novel RNAi Therapeutic Onpattro (patisiran) in Germany

Shots:

  • EU approval is based on results of APOLLO P-III study involving 19 countries in ratio (2:1) assessing Onpattro vs PBO once q3w for 18mos showing safety and efficacy
  • Onpattro RNA interference (RNAi) will be launch in Germany for the treatment of Hereditary Transthyretin-Mediated (hATTR) with improved QoL
  • Onpattro is an IV RNAi therapeutic developed to treat Amyloidosis (hATTR Amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy. It is based on RNAi- a Nobel Prize-winning Mechanism and received EU and FDA approval in Aug 2018

Ref: Alnylam | Image: BusinessWire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions